Although, the combination therapy produced remarkable neurogenesis in the formerly infarct core and beyond in the islet of regeneration, it wasn’t more efficient in reducing the mortality rate and improving the post-stroke recovery than G-CSF treatment alone (40). The gene discussed is CSF3; the disease is stroke disorder.